Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(60.0%)

N/A

1(20.0%)

Early Phase 1

1(20.0%)

5Total

Phase 1(3)

N/A(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05369754Early Phase 1Unknown

A Phase Ia Clinical Study to Evaluate the Safety, Tolerability, PK and Immunogenicity of YBSW015 in Healthy Subjects

Role: lead

NCT03414892Phase 1Completed

Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus

Role: lead

NCT04177446Not ApplicableUnknown

A Study About Nutritional Support of Enhanced Protein in Critical Patients

Role: collaborator

NCT03171623Phase 1Completed

The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride

Role: lead

NCT02599337Phase 1Completed

Bioequivalence Study of Sorafenib Tablet and Nexavar

Role: lead

All 5 trials loaded